IVA337

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

9mo

IVAPhase 3$1.4B

IVA337 Phase 3 Results Expected

IVA337• NASH - Nonalcoholic Steatohepatitis1,000

Dec 30Estimated

00%

Competitive Landscape

3 competitors in NASH - Nonalcoholic Steatohepatitis

Drug Information

Target Indication

NASH - Nonalcoholic Steatohepatitis

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

IVA

Inventiva S.A.

Related Pipeline

Mucopolysaccharidosis VI